Article
Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology - 1 Apr 2016
Marotta P, Bailey R, Elkashab M, Farley J, Feinman S V, Peltekian K, Poliquin M, Witt-Sullivan H, Rampakakis E, Drolet M, Cooper C
Abstract excerpt
The purpose of this investigation was to assess the real-life effectiveness of pegylated interferon (peg-IFN) α-2b with ribavirin (RBV) in a cohort of treatment-naïve patients with chronic genotypes 2 (G2) or 3 (G3) hepatitis C virus (HCV) infection. A post-hoc pooled analysis of two Canadian multicenter, observational studies, RediPEN and PoWer, was carried out. A total of 1242 G2- or G3-infected patients were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.